跳至主要内容
临床试验/NCT00843063
NCT00843063已完成4 期

Famotidine vs. Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion - a Randomized Controlled Study

Ruttonjee Hospital1 个研究点 分布在 1 个国家目标入组 161 人开始时间: 2004年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
161
试验地点
1
主要终点
The primary end-point was the recurrence of dyspeptic or complicated ulcer / erosions.

研究概览

简要总结

Low-dose aspirin can prevent cerebral and cardiovascular accidents in individuals with symptomatic atherothrombotic disease, but its use is frequently limited by gastrointestinal side effects.

The position of H2-receptor antagonists as a step-down therapy after healing of peptic ulcer or erosions by proton pump inhibitor is unclear.

The objective of this randomized, double blinded control study was to compare the efficacy of high-dose famotidine with pantoprazole in the prevention of recurrent dyspeptic or complicated ulcer/ erosions in patients taking low-dose aspirin

详细描述

Low-dose aspirin can prevent cerebral and cardiovascular accidents in individuals with symptomatic atherothrombotic disease . Its use is frequently limited by gastrointestinal side effects, ranging from dyspepsia (31%) to life-threatening bleeding or perforation of gastroduodenal ulcers (3.1%) over a period of 4 years .

The best approach for the secondary prevention of low-dose aspirin induced symptomatic peptic ulcer or erosions in patients who need to continue aspirin remain uncertain. At present, eradication of Helicobacter pylori infection and long-term maintenance with proton pump inhibitor PPI appears to be the best options.

The position of H2-receptor antagonists (H2RA) as a step-down therapy after healing of peptic ulcer or erosions is unclear.

The objective of this randomized, double blinded control study was to compare the efficacy of high-dose famotidine with pantoprazole in the prevention of recurrent dyspeptic or complicated ulcer/ erosions in patients taking low-dose aspirin.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • upper GIB or dyspepsia due to peptic ulcers / erosions while receiving low-dose aspirin with a daily dose ranging from 80 mg to 320 mg
  • endoscopy revealed a gastric or duodenal ulcers of 3 mm or more in diameter with unequivocal depth, or more than 5 erosions in the stomach or duodenum
  • they required continuous low-dose aspirin for the secondary prevention of coronary heart disease, peripheral vascular disease and ischemic stroke or transient ischemic attacks
  • 18 years old or older.

排除标准

  • concurrent erosive or ulcerative esophagitis
  • pyloric stenosis
  • previous gastric or duodenal surgery other than oversewing of a perforation
  • thrombocytopenia
  • renal failure with estimated creatinine clearance less than 10 ml / min
  • active cancer
  • known allergic to aspirin, famotidine or pantoprazole
  • pregnancy, lactation, child-bearing potential in the absence of contraception
  • psychosomatic disorder
  • planned co-prescription of nonsteriodal anti-inflammatory drugs corticosteriod, or anticoagulant
  • disorders that might modify the absorption of study drugs

研究组 & 干预措施

pantoprazole

Active Comparator

pantoprazole 20 mg om and matching placebo nocte

干预措施: pantoprazole vs famotidine (Drug)

famotidine

Active Comparator

Famotidine 40 mg om and nocte

干预措施: pantoprazole vs famotidine (Drug)

结局指标

主要结局

The primary end-point was the recurrence of dyspeptic or complicated ulcer / erosions.

时间窗: 48 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验